A retrospective cohort study in Canada found that the relative risk for major cardiovascular events with or without heart failure increased in adults ages 18 to 39 years with an eGFR below 80 mL/min/1.73 m2.
19 Sep 2023
A coauthor of “The Top 100 Drug Interactions” offers advice for improved management of colchicine.
1 Sep 2023
The guideline from the American Heart Association and the American College of Cardiology emphasizes coordinating care between cardiovascular and primary care professionals and prioritizing symptom relief and quality of life, among other recommendations.
1 Aug 2023
An expert discusses causes and effects of health disparities as well as ways to incorporate health equity into the practice of medicine.
1 Jul 2023
A 45-year-old man is evaluated during a routine visit. He reports no symptoms, and his medical and family history are unremarkable. Following a physical exam, what is the most appropriate cardiovascular disease assessment?
5 Sep 2023
Researchers in Sweden found that patients who had had a myocardial infarction (MI) and reported moderate or severe musculoskeletal pain one year after hospital discharge were at higher risk for death than those without pain.
22 Aug 2023
Talking about diet and exercise habits in mid-life can help guard against incremental weight gain.
1 Feb 2023
Rapid uptitration of oral HF therapies after HF hospitalization was safe, effective across LVEF categories
A high-intensity care strategy was associated with a reduced risk of death or heart failure (HF) readmission at 180 days in patients hospitalized for acute HF, regardless of left ventricular ejection fraction (LVEF), a prespecified analysis of a randomized trial found.
30 May 2023
The election of Officers and Regents has been completed, and terms become effective at the conclusion of the Annual Business Meeting and Town Hall at Internal Medicine Meeting 2023 in San Diego.
1 Mar 2023
Adding a sodium-glucose cotransporter-2 inhibitor to standard care had intermediate cost-effectiveness, but replacing an angiotensin-converting enzyme inhibitor with an angiotensin receptor-neprilysin inhibitor was only borderline cost-effective, a modeling study found.
13 Jun 2023